301015.SZ SHZ
Qingdao Baheal Medical Inc.
1W: -2.8%
1M: +4.6%
3M: +26.6%
YTD: +7.5%
1Y: +2.8%
3Y: +2.9%
¥25.68 ($3.83)
+0.64 (+2.56%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$8.1B
-2.0% ▼
5Y CAGR: +10.8%
Gross Profit
$2.9B
+4.2% ▲
5Y CAGR: +16.3%
Operating Income
$978M
-6.3% ▼
5Y CAGR: +27.0%
Net Income
$692M
-2.9% ▼
5Y CAGR: +26.9%
EPS (Diluted)
$1.28
-3.8% ▼
5Y CAGR: +26.2%
EBITDA
$1.0B
-6.9% ▼
5Y CAGR: +24.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $5.9B | $7.1B | $7.5B | $8.3B | $8.1B |
| YoY Growth | +21.3% | +19.9% | +6.5% | +9.9% | -2.0% |
| Cost of Revenue | $4.4B | $5.3B | $5.4B | $5.5B | $5.2B |
| Gross Profit | $1.5B | $1.8B | $2.1B | $2.8B | $2.9B |
| Gross Margin | 24.9% | 25.2% | 27.7% | 33.3% | 35.4% |
| R&D Expenses | $0 | $0 | $5M | $42M | $36M |
| SG&A Expenses | $1.0B | $1.1B | $1.3B | $1.6B | $1.8B |
| Operating Expenses | $1.1B | $1.2B | $1.4B | $1.7B | $1.9B |
| Operating Income | $368M | $561M | $674M | $1.0B | $978M |
| Operating Margin | 6.3% | 8.0% | 9.0% | 12.6% | 12.1% |
| Interest Expense | $65M | $66M | $62M | $64M | $82M |
| Income Before Tax | $371M | $565M | $669M | $1.0B | $967M |
| Tax Expense | $94M | $150M | $179M | $257M | $200M |
| Net Income | $273M | $422M | $507M | $712M | $692M |
| Net Margin | 4.6% | 6.0% | 6.7% | 8.6% | 8.5% |
| EPS (Diluted) | $0.52 | $0.80 | $0.96 | $1.33 | $1.28 |
| EBITDA | $433M | $637M | $736M | $1.1B | $1.0B |
| Shares Outstanding | 525M | 525M | 525M | 534M | 540M |